{
    "clinical_study": {
        "@rank": "62038", 
        "arm_group": {
            "arm_group_label": "infusion group", 
            "arm_group_type": "Experimental", 
            "description": "Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor."
        }, 
        "brief_summary": {
            "textblock": "Poor graft function (PGF) is a common complication after allogeneic stem cell\n      transplantation, which was associated with high mortality. The pathogenesis fo PGF was\n      poorly understood. Infusion of donor peripheral cell harvest was effective for some patients\n      with PGF in our preliminary study. This present study aimed to explore the efficacy of\n      peripheral cell harvest for poor graft function."
        }, 
        "brief_title": "G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Poor Graft Function,", 
            "Stem Cell Transplantaion,", 
            "Graft Versus Host Disease"
        ], 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "Poor graft function (PGF) is a common complication after allogeneic stem cell\n      transplantation, which was associated with high mortality. The pathogenesis fo PGF was\n      poorly understood. Infusion of donor peripheral cell harvest was effective for some patients\n      with PGF in our preliminary study.The peripheral cell harvest was aphaeresis on the fourth\n      or fifth day after mobilization with recombinant human granulocyte colony stimulating\n      factor. Hematogical response was assessed at 30 days after infusion. Good response was\n      defined as neutrophil > 1.0\u00d7109/l without G-CSF support for at least 3 consecutive days, and\n      persistent platelet >20\u00d7109/l without transfusion for at least 7 days. Otherwise, poor\n      response was defined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients received allogeneic stem cell transplantation;diagnosis of PGF after HSCT;\n             without concurent GVHD,RELAPSE of underlying disease.\n\n        Exclusion Criteria:\n\n          -  age<14 years;active GVHD;relapse of underlying disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857336", 
            "org_study_id": "2013-03"
        }, 
        "intervention": {
            "arm_group_label": "infusion group", 
            "intervention_name": "infusion of G-CSF mobilized peripheral harvest", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "sunyuqian83@hotmail.com", 
                "last_name": "Yu-Qian SUN, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100044"
                }, 
                "name": "Peking University Institute of Hematology"
            }, 
            "investigator": {
                "last_name": "Xiao-Jun HUANG, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation", 
        "overall_contact": {
            "email": "sunyuqian83@hotmail.com", 
            "last_name": "Yu-Qian SUN, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hematogical response was assessed at 30 days after infusion. Good response was defined as neutrophil > 1.0\u00d7109/l without G-CSF support for at least 3 consecutive days, and persistent platelet >20\u00d7109/l without transfusion for at least 7 days. Otherwise, poor response was defined.", 
            "measure": "hematological response", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857336"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "Xiaojun Huang", 
            "investigator_title": "Peking University Institute of Hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}